Clinical Trials Browser

Recruiting × liposomal doxorubicin × Lymphoid × Clear all

NCT03618550 2025-12-02

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease, Recurrence